# JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

> **NCT06380348** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 398 (estimated)

## Conditions studied

- Local Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** JMT101 Injection
- **DRUG:** Osimertinib tablet
- **DRUG:** Cisplatin injection
- **DRUG:** Pemetrexed injection

## Key facts

- **NCT ID:** NCT06380348
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-26
- **Primary completion:** 2027-03-26
- **Final completion:** 2028-03-26
- **Target enrollment:** 398 (ESTIMATED)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06380348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06380348, "JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06380348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*